Such different sartans. Place of candesartan


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

This review article presents current data about sartans, one of the main classes of drugs used to treat cardiovascular diseases combined with brain damage, kidney disease, and metabolic disorders. Along with the general properties of sartans, information about the distinctive features of each of them, allowing to personalize the treatment of patients depending on the clinical situation, is discussed. Particular attention is paid to the candesartan as a drug with the longest (more than one day) period of action, and a sufficient evidence base.

Full Text

Restricted Access

About the authors

Igor I. Shaposhnik

South Ural State medical university

Email: shaposhnik@yandex.ru
MD, professor, head of the Department of propaedeutics of internal diseases

References

  1. Еремина Ю.Н., Леонова М.В., Галицкий А.А. Антагонисты рецепторов к ангиотензину II: обзор эффективности и безопасности. Consilium medicum. 2013;1:25-9. [Yeremin Yu.N., Leonova M. V., Galitsky A.A. Antagonists of receptors to angiotensin II: a review of efficacy and safety. Consilium medicum. 2013;1:25-9 (in Russ.)]
  2. Рекомендации ESC по диагностике и лечению острой и хронической сердечной недостаточности 2016. РМЖ. 2017;1:7-81. [ESC guidelines on the diagnosis and treatment of acute and chronic heart failure 2016. Russian journal of cardiology. 2017;1:7-81 (in Russ.)]
  3. Nixon R.M., Muller E., Lowy A., Falvey H. Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a metaanalytical approach. Int. J. Clin. Pract. 2009;63(5):766-75.
  4. Fagard R.H., Celis H., Thijs L., Wouters S. Regression of left ventricular mass by antihypertensive treatment: a meta-analysis of randomized comparative studies. Hypertension. 2009;54:1084-91.
  5. Kunz R., Friedrich C., Wolbers M., Mann J. Meta-analysis: Effect of monotherapy and combination therapywithinhibitors of the renin-angiotensin system on proteinuria in renal disease. Ann. Intern. Med. 2008;148:30-48.
  6. Blood pressure lowering treatment trialists collaboration, Turnbull F., Neol B., PfeferM., Kostis J., Algert C., Woodward M., Chalmers J., Zanchetti A., MacMahon S. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J. Hypertens. 2007;25:951-8.
  7. Bangalore S., Parkar S., Grossman E., Messerli F. A meta-analysis of 94,492 patients with hypertension treated with beta-blockers to determine the risk of new-onset diabetes mellitus. Am. J. Cardiol. 2007;100(8):1254-62.
  8. Goette A., Schon N., Kirchhof P., Breithardt G., Fetsch T., Häusler K.G., Klein H.U., Steinbeck G., Wegscheider K., Meinertz T. Angiotensin II-antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial. Circ. Arrhyshm. Electrophysiol. 2012;5(1):43-51.
  9. Недогода С.В., Чумачок Е.В., Ледяева А.А., Цома В.В. Возможности коррекции гиперурикемии лозартаном при метаболическом синдроме и артериальной гипертензии. Кардиоваскулярная терапия и профилактика. 2011;6:24-30. [Nedogoda S.V., Chumachok Ye.V., Ledyaeva A.A., Tsoma V.V. Correction of hyperuricemia with losartan in metabolic syndrome and hypertension. Cardiovascular therapy and prevention. 2011;6:24-30 (in Russ.)]
  10. Cohn J.N., Tognoni G. Valsartan heart failure trial investigators: A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N. Engl. J. Med. 2001;345(23):1667-75.
  11. Драпкина О.М., Фомичева Е.И. Кардиометаболические свойства телмисартана: новые перспективы для использования. Рациональная фармакотерапия в кардиологии. 2015;11(6):650-4. [Drapkina O.M., Fomicheva Ye.I. Cardiometabolic properties of telmisartan: new perspectives for use. Rational pharmacotherapy in cardiology. 2015;11(6):650-4 (in Russ.)]
  12. Подзолков В.И., Тарзиманова А.И. Значение ирбесартана в клинической практике. Рациональная фармакотерапия в кардиологии. 2014;10(6):654-9. [Podzolkov V.I., Tarzimanova A.I. The value of irbesartan in clinical practice. Rational pharmacotherapy in cardiology. 2014;10(6):654-9 (in Russ.)]
  13. Барышникова Г.А., Чорбинская С.А., Степанова И.И., Чупрова Н.В. Роль олмесартана в клинической практике. Consilum medicum. 2013;1:18-22. [Baryshnikova G.A., Chorbinskaya S.A., Stepanova 1.1., Chuprova N.V. The role of olmesartan in clinical practice. Consilum medicum. 2013;1:18-22 (in Russ.)]
  14. Скибицкий В.В., Фендрикова А.Ф., Сиротенко Д.В., Скибицкий А.В. Хронотерапевтические аспекты эффективности азилсартана медоксомила в составе комбинированной терапии у пациентов с артериальной гипертонией и метаболическим синдромом. Кардиология. 2016;10:35-40. [Skibitsky V.V., Fendrikova A.F., Sirotenko D.V. Skibitsky A.V. Chronotherapeutics efficiency aspects of azilsartan medoxomil as part of combination therapy in patients with arterial hypertension and metabolic syndrome. Kardiologiia. 2016;10:35-40 (in Russ.)]
  15. Диагностика и лечение артериальной гипертонии (клинические рекомендации). Кардиологический вестник. 2015;1:5-30. [Diagnosis and treatment of hypertension (clinical practice guidelines).Kardiologichesky vestnik. 2015;1:5-30 (in Russ.)]
  16. Lithell H., Hansson L., Skoog I., Elmfeldt D., Hofman A., Olofsson B., Trenkwalder P., Zanchetti A.; SCOPE Study Group. The study on cognition and prognosis in the elderly (SCOPE): principal results of a randomized double-blind intervention trial. J. Hypertens. 2003;21(5):875-86.
  17. Lonn E., Bosch J., Lopez-Jaramillo P., Zhu J., Liu L., Pais P., Diaz R., Xavier D., Sliwa K., Dans A., Avezum A., Piegas L.S., Keltai K., Keltai M., Chazova I., Peters R.J., Held C., Yusoff K., Lewis B.S., Jansky P., Parkhomenko A., Khunti K., Toff W.D., Reid C.M., Varigos J., Leiter L.A., Molina D.I., McKelvie R., Pogue J., Wilkinson J., Jung H., Dagenais G., Yusuf S.; HOPE-3 Investigators. Blood-Pressure lowering in intermediate-risk persons without cardiovascular disease. N. Engl. J. Med. 2016;374(21):2009-20.
  18. Pfeffer M.A., Swedberg K., Granger C.B., Held P., McMurray J.J., Michelson E.L., Olofsson B., Ostergren J., Yusuf S., Pocock S.; CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall program. Lancet. 2003;362(9386):759-66.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2017 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies